Related and Nonrelated Parties [Axis]
Related Party [Member]
Class of Stock [Axis]
Series A Convertible Preferred Stock [Member]
Series B1 Convertible Preferred Stock [Member]
Series B2 Convertible Preferred Stock [Member]
Nonrelated Party [Member]
Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Series B1 Preferred Stock [Member]
Series B2 Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Sale of Stock [Axis]
Private Placement [Member]
Series B-2 Convertible Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Private Investment in Public Equity [Member]
Asset Purchase Agreement [Member]
Pre Funded Warrant [Member]
Series B-1 convertible preferred stock [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Financial Instrument [Axis]
Warrant [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Long-Lived Asset, Class [Axis]
Furniture and Fixtures [Member]
Computer Equipment [Member]
Equipment [Member]
Antidilutive Securities [Axis]
Restricted Stock Units (RSUs) [Member]
Lease Contractual Term [Axis]
Lease Agreement [Member]
Pledging Purpose [Axis]
Letter of Credit [Member]
Location, Statement of Income, Balance [Axis]
Debt Instrument [Axis]
Senior Convertible Note [Member]
Former Officer [Member]
Promissory Note [Member]
Revolving Note Agreement [Member]
Convertible Bridge Notes [Member]
Statistical Measurement [Axis]
Maximum [Member]
Lenders [Member]
Title and Position [Axis]
Dr. Anatoly Dritschilo [Member]
Award Type [Axis]
Closing Cash [Member]
First Installment [Member]
Second Installment [Member]
Consulting Agreement [Member]
Pre-Funded Warrants [Member]
Accelerated Portion of The First Installment [Member]
Six Month Installment [Member]
Twelve Month Installment [Member]
Technology Development Milestone 1 [Member]
Technology Development Milestone 2 [Member]
Series B-1 Preferred Stock [Member]
March 2025 Equity Financings [Member]
West Park Capital Inc [Member]
November 2025 Equity Financings [Member]
Alternative Investment Capital Inc [Member]
March 2026 Equity Financing [Member]
Series B-2 Preferred Stock [Member]
Securities Purchase Agreement [Member]
October 2024 Equity Financing [Member]
Plan Name [Axis]
2018 Equity Incentive Plan [Member]
Directors, Officers and Consultants [Member]
Joseph Tung [Member]
Steve Richards and Joseph Tung [Member]
Alto Convertible Note [Member]
May 2026 PIPE Warrants [Member]
Measurement Input Type [Axis]
Measurement Input, Share Price [Member]
Minimum [Member]
Measurement Input, Exercise Price [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Dividend Rate [Member]
Sponsored Research Agreement [Member]
Theradex Systems Inc [Member]
Consolidation Items [Axis]
Operating Segments [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement [Table]
Statement [Line Items]
Assets
Current assets
Cash and cash equivalents
Prepaid expenses and other current assets
Total current assets
Investment in United Dogecoin
Property and equipment, net
Intangible assets, net
Deferred financing costs
Operating lease right-of-use asset
Total Assets
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable and accrued expenses
Contingent consideration liability
Consideration payable
Operating lease liability
Due to United Dogecoin
Total current liabilities
Derivative liability
Operating lease liability non-current
Total Liabilities
Commitments and contingencies (Note 10)
Stockholders’ Equity
Preferred Stock, value
Common stock, $0.00001 par value; 100,000,000 shares authorized; 1,001,165 shares issued and outstanding at June 30, 2026; 202,362 shares issued and outstanding at December 31, 2025
Additional paid in capital
Accumulated deficit
Total Stockholders’ Equity
Total Liabilities and Stockholders’ Equity
Preferred stock, par value
Preferred stock, liquidation value per share
Preferred stock, shares authorized
Preferred stock, shares outstanding
Preferred stock, shares issued
Preferred stock, liquidation preference, value
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Revenue
Operating expenses
Research and development
General and administrative
Legal and professional
Total operating expenses
Net loss from operations
Other (expense) income
Interest expense
Interest income
Change in fair value of derivative liabilities
Change in fair value of convertible notes
Gain on extinguishment of debt
Total other (expense) income
Net loss
Weighted average common shares outstanding - basic
Weighted average common shares outstanding - diluted
Net loss per shares - basic
Net loss per shares - diluted
Balance
Balance, shares
Common stock issued for restricted stock units
Common stock issued for restricted stock units, shares
Issuance of common stock and pre-funded warrants, net of issuance costs of $275,000
Issuance of common stock and pre-funded warrants, net of issuance fees, shares
Exercise of pre-funded warrants
Exercise of pre-funded warrants, shares
Stock-based compensation
Net loss
Issuance of Series B-1 preferred stock and Milestone Pre-Funded Warrants pursuant to Molecule.ai Second Amendment
Issuance of Series B-1 preferred stock pursuant to Molecule.ai Second Amendment, shares
Prepaid share repurchase pursuant to Molecule.ai Second Amendment
Issuance of Series B-1 and Series B-2 Convertible Preferred Stock and 2026 Pre-Funded Warrants pursuant to the United Dogecoin Merger Agreement and PIPE, net of issuance costs of $1,207,032
Issuance of Series B-1 preferred stock pursuant to United Dogecoin Merger Agreement, shares
Common stock issued for reverse stock split fractional share round up
Common stock issued for reverse stock split fractional share round up, shares
Capitalized cost related to United Dogecoin replacement options
Partial conversion of convertible note at fair value
Partial conversion of convertible note at fair value, shares
Reversal of issuance costs in relation to November 2025 offering costs
Common stock issued for Molecule.ai Asset Acquisition
Balance
Balance, shares
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock and pre-funded warrants, net of issuance costs
Payments of Stock Issuance Costs
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Change in fair value of derivative liabilities
Amortization of debt discount and finance fees
Financial advisor fee settled with Series B-1 Preferred Stock and Pre-Funded Warrants
Stock-based compensation
Interest payments on convertible notes accounted for at fair value
Change in fair value of convertible notes
Gain on extinguishment of debt
Changes in operating assets and liabilities:
Prepaid expenses
Due to United Dogecoin
Accounts payable and accrued expenses
Accrued interest payable - related parties
Change in operating lease asset and liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of capitalized software
Payment of installment payments related to Molecule.ai Asset Acquisition
Payment of contingent consideration related to Molecule.ai Asset Acquisition
Net cash used in provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of note payable-related party
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs
Proceeds from PIPE Financing, net of issuance costs paid
Payment of other issuance costs for issuance of common stock and equity-classified warrants
Proceeds from exercise of pre-funded warrants
Payment of finance costs
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Cash paid for:
Interest
Income taxes
Supplemental non-cash financing activities:
Issuance of Series B-1 Convertible Preferred Stock and 2026 Pre-Funded Warrants as a financial advisor fee
May 2026 PIPE proceeds included in Investment in United Dogecoin
Issuance costs in accounts payable and accrued expenses
Issuance of Series B-1 Preferred Stock and pre-funded warrants pursuant to Molecule.ai Second Amendment
Noncash prepayment of share repurchase pursuant to Molecule.ai Second Amendment
Capitalized cost related to United Dogecoin replacement options
Issuance of Series B-1 Convertible Preferred Stock and 2026 Pre-Funded Warrants pursuant to the United Dogecoin Merger Agreement
Conversion of convertible notes accounted for at fair value
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Trading Arrangements, by Individual [Table]
Trading Arrangement [Axis]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Liquidity
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Leases
Leases
Notes Payable-related Party
Notes Payable-Related Party
Debt Disclosure [Abstract]
Convertible Notes and Loan Agreement
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
Molecule.ai Asset Acquisition
United Dogecoin Merger Agreement
Equity [Abstract]
Stockholders’ Equity
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Business Segment Information
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Reverse Stock Splits
Basis of Consolidation
Use of Estimates
Cash and Cash Equivalents
Investment in Equity Securities
Fair Value of Financial Instruments
Derivative Financial Instruments
Convertible Notes Payable
Convertible Preferred Stock
Warrants
Stock-Based Compensation
Research and Development Expenses
Leases
Impairment of Long-Lived Assets
Property and Equipment
Internal-Use Software
Intangible Assets
Income Taxes
Segment Information
Net Loss Per Common Stock
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Cash and Cash Equivalents
Schedule of Fair Value Liabilities Measured on Recurring Basis
Schedule of Useful Lives for Property Plant Equipment
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Right-of Use Asset and Lease Information about Operating Lease
Schedule of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability
Schedule of Fair Value Measurement using Significant Unobservable Inputs
Schedule of Total Purchase Consideration
Schedule of Carrying Value of Development Technology Asset
Schedule balance of Investment in United Dogecoin
Schedule of Warrants Activity
Schedule of Restricted Stock Units (RSUs)
Schedule of Compensation Expenses (RSUs)
Schedule of Weighted Average Grant Date Fair Value of Stock Options Granted
Schedule of Option Activity
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Schedule of Key Inputs for Valuation Assumptions
Schedule of Derivative Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued
Net loss
Revenues
Working capital
Issuance of shares
Warrants to purchase common stock
Warrant exercise price
Gross proceeds
Net proceeds
Proceeds from other equity
ScheduleOfSignificantAccountingPoliciesTable [Table]
Stockholders' Equity, Reverse Stock Split
Cash FDIC insured amount
Preferred stock, liquidation preference per share
Cash
Money market funds
Total cash and cash equivalents
Derivative Liability - Warrants
Total Liabilities
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Property plant and equipment useful life
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Schedule Of Right-of Use Asset And Lease Information About Operating Lease
Operating lease cost
Variable lease cost
Sublease income
Total lease cost
Cash paid for operating cash flows for operating leases
Weighted-average remaining lease term - operating leases (year)
Weighted-average discount rate - operating leases
Schedule Of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability
2026 (Excluding the six months ended June 30, 2026)
2027
2028 and thereafter
Total future minimum lease payments
Less: imputed interest
Present value of payments
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Line Items]
Base rent
Lease term
Rent variable rate
Lease commencement
Percentage of rent abatement
Security deposit
Common area maintenance cost
Sublease income
Non-cash impairment charges
Proceeds from issuance of debt
Interest rate
Maturity date
Warrants to purchase shares of common stock
Warrants exercise price
Proceeds from issuance of debt
Interest amount
Senior convertible debt
Stock conversion
Interest expense, operating and nonoperating
Principal repaid
Balance - December 31, 2024
Conversion of convertible bridge note (at fair value)
Payments of coupon interest
Gain on change in fair value
Balance - December 31, 2025
Principal amount
Deferred loan costs
Interest expense
Convertible notes payable
Interest rate
Original issue discount percentage
Outstanding balance percentage
Warrants exercisable
Warrants expiring
Convertible note
Repayment of convertible note
Secured debt
Proceeds from secured debt
Common stock issuable upon mandatory conversion
Fair value of common stock per share
Total purchase consideration
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Contingent consideration liability
Carrying value of development technology asset, beginning balance
Developed technology acquired
Amortization expense
Software in progress
Carrying value of development technology asset, ending balance
Business Combination [Table]
Business Combination [Line Items]
Purchase consideration
Equity issuance percentage
Contingent consideration
Shares issued for asset acquisition
Shares issued for asset acquisition, value
Asset acquisition transaction expenses
Developed technology asset useful life
Shares issued
Cash payment
Installment exercisable
Iinstallment exercisable total
Cancellation shares
Fair value of shares and warrants
Amount of increase decrease in net settlement
Prepaid shares repurchase
Prepaid share repurchase, reduction in additional paid in capital
Issuance of Series B-1 Convertible Preferred Stock and Milestone Pre-Funded Warrants in the Merger Agreement
PIPE proceeds invested to support operations
Stock-based compensation related to replacement options
Ending investment at June 30, 2026
Issuance of convertible, shares
Conversion price
Pre Funded Warrants at fair value
Warrants at fair value initial cost
Investment United Dogecoin
Issuance of shares acquisitions
Issuance of shares acquisitions
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding, balance
Weighted average exercise price, outstanding balance
Weighted average life (years)
Number of warrants, granted
Weighted average exercise price, granted
Granted average life years
Number of warrants outstanding, balance
Weighted average exercise price, outstanding balance
Number of RSUs, Outstanding, Beginning Balance
Weighted Average Grant Date Fair Value Per RSU, Beginning Balance
Number of RSUs, Forfeited
Weighted Average Grant Date Fair Value Per RSU, Forfeited
Number of RSUs, Vested
Weighted Average Grant Date Fair Value Per RSU, Vested
Number of RSUs, Outstanding, Ending Balance
Weighted Average Grant Date Fair Value Per RSU, Ending Balance
Total
Dividend Yield
Expected Life (Years)
Risk-free rate of interest for expected life
Volatility
Stock Price
Strike Price
Outstanding, shares
Outstanding, weighted average exercise price
Granted, shares
Granted, weighted average exercise price
Outstanding, shares
Outstanding, weighted average exercise price
Outstanding weighted average remaining contractual term
Exercisable, shares
Exercisable, weighted average exercise price
Number of RSUs granted
Issuance of shares
Reverse stock split fractional shares
Issuance of stock, convertible shares
Debt, principal
Conversion rate
Public offering price per share
Gross proceeds from offering
Proceeds from issuance of equity
Offering expenses
Percentage of shares outstanding
Warrants exercised
Prefunded warrants shares
Number of shares sold, value
Placement agent fees, legal costs and other expenses
Underwriting discounts
Warrants exercised
Debt Instrument, Convertible, Conversion Price
Purchase of assets
Conversion price
Issuance costs
Stock issued during period value other
Warrants to purchase shares of common stock
Warrants unexercised and outstanding
Aggregate intrinsic value of warrants
Common stock authorized for issuance
Number of shares granted
Number of shares vested
Fair value of RSUs granted
Stock-based compensation expense
Number of RSUs vested
Fair value of common stock
Number of RSUs forfeited
Number of RSUs outstanding
Unrecognized compensation cost
Weighted average term for recognition
Outstanding, shares
Capitalized cost related to united dogeco in replacement options
Reclassification out of Accumulated Other Comprehensive Income [Table]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Warrants measurement input
Time period (years)
Beginning balance
Loss on change in fair value
Issuance of May 2026 PIPE Warrants
Ending balance
Warrant value
Cost of license to intellectual property
Prepayment of research costs
Amortization of costs
Total costs limit
Aggregate costs
Outstanding amount owed
Repayment of debt
Wind down costs
Cosultant fees for services
Expenses recognized
Accrued Professional Fees
Consulting fees paid
Consulting costs
General and administrative expenses
Segment Reporting [Table]
Segment Reporting [Line Items]
Number of operating segments
Third-party contract research organization expenses
Payroll expenses
Subsequent Event [Table]
Subsequent Event [Line Items]
Merg agreements description
Number of shares authorized for issuance
Conversion of shares issued
Common stock purchase warrants
Investment in united dogecoin.
Series A Convertible Preferred Stock [Member]
Series B1 Convertible Preferred Stock [Member]
Series B2 Convertible Preferred Stock [Member]
Change In Fair Value Of Convertible Notes.
Loss on extinguishment of contingent payable.
Series B1 Preferred Stock [Member]
Series B2 Preferred Stock [Member]
Issuance of common stock and pre-funded warrants, net of issuance costs.
Issuance of series b1 preferred stock pursuant to united dogeco in merger agreement.
Reversal of issuance costs in relation to offering costs.
Stock issued during period value reverse stock splits.
Issuance of prefunded warrants in pipe net of issuance costs.
Prefunded warrants in pipe net of issuance costs.
Preferred stock in pipe net of issuance costs.
Issuance of series b2 preferred stock in pipe net of issuance costs.
Issuance of series b1 preferred stock pursuant to united dogeco in merger agreement shares.
Issuance of series b2 preferred stock in pipe net of issuance costs shares.
Interest payments on convertible notes accounted for at fair value.
Increase decrease in accrued interest payable related parties.
Issuance costs in accounts payable and accrued expenses.
Gain on marketable securities.
Noncash pipe proceeds included in due from united dogecoin.
Issuance of series b1 preferred stock and prefunded warrants pursuant to molecule ai second amendment.
Prepayment of share repurchases pursuant to molecule ai second amendment.
Capitalized cost related to united dogeco in replacement options.
Payments of stock issuance costs one.
Issuance of Series B-1 preferred stock pursuant to Molecule.ai Second Amendment.
Issuance of Series B-1 preferred stock pursuant to Molecule.ai Second Amendment, shares.
Working capital.
Reverse Stock Split [Policy Text Block]
Convertible Note [Policy Text Block]
Warrants [Policy Text Block]
Schedule Of Useful Lives For Property Plant Equipment [Table Text Block]
Recently Issued Accounting Pronouncements [Policy Text Block]
Lease Agreement [Member]
Rent variable rate1.
Percentage of rent abatement.
Common area maintenance cost.
Lessee operating lease liability payments due year three and thereafter.
Notes Payable Related Party Disclosure [Text Block]
Senior Convertible Note [Member]
Former Officer [Member]
Promissory Note [Member]
Revolving Note Agreement [Member]
Convertible Bridge Notes [Member]
Lenders [Member]
Dr. Anatoly Dritschilo [Member]
Asset Purchase Agreement [Member]
Closing Cash [Member]
First Installment [Member]
Second Installment [Member]
Equity issuance percentage.
Consulting Agreement [Member]
Series B-1 convertible preferred stock [Member]
Series B-2 Convertible Preferred Stock [Member]
Technology Development Milestone 1 [Member]
Technology Development Milestone 2 [Member]
Private Investment In Public Equity [Member]
Pre Funded Warrant [Member]
Pre-Funded Warrants [Member]
Series B-1 Preferred Stock [Member]
March 2025 Equity Financings [Member]
West Park Capital Inc [Member]
Percentage Of Shares Outstanding.
November 2025 Equity Financings [Member]
Alternative Investment Capital Inc [Member]
March 2026 Equity Financing [Member]
Series B-2 Preferred Stock [Member]
Securities Purchase Agreement [Member]
October 2024 Equity Financing [Member]
Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.
Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.
Weighted Average Remaining Life in Years Outstanding,
Share-based compensation arrangement by share-based payment award non-options outstanding intrinsic value.
2018 Equity Incentive Plan [Member]
Directors, Officers and Consultants [Member]
Joseph Tung [Member]
Steve Richards and Joseph Tung [Member]
Alto Convertible Note [Member]
Derivative gain loss on derivative warrants.
Sponsored Research Agreement [Member]
Prepayment of research costs.
Theradex Systems Inc [Member]
Aggregate costs.
Sharebased compensation arrangement by sharebased payment award non options outstanding granted weighted average remaining contractual term.
Prefunded warrants shares.
May 2026 PIPE Warrants [Member]
Accelerated Portion Of The First Installment [Member]
Six Month Installment [Member]
Twelve Month Installment [Member]
Issuance costs in accounts payable and accrued expense.
Payments to acquire assets under installment agreement.
Schedule Of Consideration Payable And Contingent Consideration Payable [Table Text Block]
Liabilities extinguished through issuance of equity.
Replacement consideration issued.
Payments of other obligations.
Business combination contingent consideration liability exchanged or extinguished.
Replacement consideration issued pursuant to second amendment.
Business combination contingent consideration liability payments.
Consideration payable payments.
Fair value of milestone pre funded warrants issued.
Replacement consideration.
Carrying value of consideration payable extinguished.
Prepayment of share repurchase recorded in additional paid in capital.
Schedule Of Loss On Extinguishment Of Contingent Payable [Table Text Block]
Due to United Dogecoin
Common stock upon achievement of specified additional milestone events.
Warrants At Fair Value Initial Cost
Investment United Dogecoin [Table Text Block]
Merger Agreements description
Convertible Preferred Stock [Policy Text Block]
Financial advisor fee settled with Series B-1 Preferred Stock and Pre-Funded Warrants
Issuance of series B1 convertible preferred stock and 2026 pre funded warrants as financial advisor fee.
Issuance of series B1 convertible preferred stock and 2026 pre funded warrants pursuant to united dogecoin merger agreement.
Investment united dogecoin.
Pipe proceeds invested to support operations.
Stock based compensation related to replacement options.
Merg agreements description.
Cash payment.
Installment exercisable.
Iinstallment exercisable total.
Stock issued during period value shareholder contribution.
Stock issued during period shares shareholder contribution.
Shareholder contribution arising from TDR pursuant to Molecule.ai second amendment.
Conversion of convertible notes accounted for at fair value.
Fair value of shares and warrants.
Amount of increase decrease in net settlement.
Planned capital raise amount.
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Income (Loss)
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Shares, Outstanding
Stock Repurchased During Period, Value
Share-Based Payment Arrangement, Noncash Expense
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Due to Related Parties, Current
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Software
PaymentsToAcquireAssetsUnderInstallmentAgreement
Payment for Contingent Consideration Liability, Investing Activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Repayments of Related Party Debt
Payments of Financing Costs
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
PrepaymentOfShareRepurchasePursuantToMoleculeAISecondAmendment
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Lessee, Operating Leases [Text Block]
Equity [Text Block]
Lessee, Leases [Policy Text Block]
Lease, Cost
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Convertible Debt, Fair Value Disclosures
Debt Instrument, Periodic Payment, Interest
Debt Instrument, Interest Rate, Effective Percentage
Asset Acquisition, Contingent Consideration, Liability
Intangible Asset, Finite-Lived, after Accumulated Amortization
Intangible Asset, Finite-Lived, Amortization Expense
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations
Debt Instrument, Convertible, Liquidation Preference, Per Share
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
DerivativeGainLossOnDerivativeWarrants